 MediciNova Inc NASDAQ: MNOV says the Phase 2 trial of MN-166 ibudilast in hospitalized COVID-19 patients demonstrated significant improvements compared to placebo for all four clinical endpoints analyzed. The trial achieved statistical significance for one of the co-. 